via Fisher Center
New findings suggest a hormone called Lipocalin-2 could be used as a potential treatment for obesity
A hormone that can suppress food intake and increase the feeling of fullness in mice has shown similar results in humans and non-human primates, says a new study published today in eLife.
The hormone, called Lipocalin-2 (LCN2), could be used as a potential treatment in people with obesity whose natural signals for feeling full no longer work.
LCN2 is mainly produced by bone cells and is found naturally in mice and humans. Studies in mice have shown that giving LCN2 to the animals long term reduces their food intake and prevents weight gain, without leading to a slow-down in their metabolism.
“LCN2 acts as a signal for satiety after a meal, leading mice to limit their food intake, and it does this by acting on the hypothalamus within the brain,” explains lead author Peristera-Ioanna Petropoulou, who was a Postdoctoral Research Scientist at Columbia University Irving Medical Center, New York, US, at the time the study was carried out, and is now at the Helmholtz Diabetes Center, Helmholtz Zentrum München, Munich, Germany. “We wanted to see whether LCN2 has similar effects in humans, and whether a dose of it would be able to cross the blood-brain barrier.”
The team first analysed data from four different studies of people in the US and Europe who were either normal weight, overweight or living with obesity. The people in each study were given a meal after an overnight fast, and the amount of LCN2 in their blood before and after the meal was studied. The researchers found that in those who were of normal weight, there was an increase in LCN2 levels after the meal, which coincided with how satisfied they felt after eating.
By contrast, in people who were overweight or had obesity, LCN2 levels decreased after a meal. Based on this post-meal response, the researchers grouped people as non-responders or responders. Non-responders, who showed no increase in LCN2 after a meal, tended to have a larger waist circumference and higher markers of metabolic disease – including BMI, body fat, increased blood pressure and increased blood glucose. Remarkably, however, people who had lost weight after gastric bypass surgery were found to have a restored sensitivity to LCN2 – changing their status from non-responders before their surgery, to responders afterwards.
Taken together, these results mirror those seen in mice, and suggest that this loss of post-meal LCN2 regulation is a new mechanism contributing to obesity and could be a potential target for weight-loss treatments.
After verifying that LCN2 can cross into the brain, the team explored whether treatment with the hormone might reduce food intake and prevent weight gain. To do this, they treated monkeys with LCN2 for a week. They saw a 28% decrease in food intake compared with that before treatment within a week, and the monkeys also ate 21% less than their counterparts who were treated only with saline. Moreover, after only one week of treatment, measurements of body weight, body fat and blood fat levels showed a declining trend in treated animals.
“We have shown that LCN2 crosses to the brain, makes its way to the hypothalamus and suppresses food intake in non-human primates,” concludes senior author Stavroula Kousteni, Professor of Physiology and Cellular Biophysics at Columbia University Irving Medical Center. “Our results show that the hormone can curb appetite with negligible toxicity and lay the groundwork for the next level of LCN2 testing for clinical use.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Treatment for obesity
- What to know about semaglutide, a diabetes drug being used for weight loss that could be a 'game changer' for obesityon May 14, 2021 at 11:57 am
The medication, used to treat type 2 diabetes, is being tested for obesity, since patients taking it reported weight loss and suppressed appetite.
- Five myths about obesityon May 13, 2021 at 4:21 pm
Misinformation and shame hinder our ability to treat a common health problem.
- Obesity: New drug turns ‘energy-storing’ fat into ‘energy-burning’ faton May 13, 2021 at 8:38 am
New research in mice tests the benefits of an obesity drug that turns 'energy-storing' fat into 'energy-burning' fat by turning up the heat.
- Study shows new obesity treatment semaglutide causes similar weight loss across different age groupson May 13, 2021 at 12:37 am
The STEP trials published over the past year have established the efficacy and safety of semaglutide in treating patients with obesity. A new study analysing the effects of this treatment in different ...
- New experimental drug cagrilintide (AM833), when combined with emaglutide, shows potential for treatment of obesityon May 12, 2021 at 11:57 pm
An early study of a new experimental drug to treat obesity known as cagrilintide shows that, when combined with semaglutide 2.4 mg, the combination leads to more weight loss than semaglutide 2.4 mg ...
Go deeper with Google Headlines on:
Treatment for obesity
Go deeper with Bing News on:
- Biomarker Panel May Help Predict Kidney Damage in Patients With Alcoholic Hepatitison May 13, 2021 at 11:00 am
One of the first studies of its kind has concluded that interleukin-18 (IL-18) appears to be a specific biomarker of serious kidney damage in patients with alcoholic hepatitis.
- Journal of biological inorganic chemistryon May 11, 2021 at 5:01 pm
The interaction between lipocalin 2 and dipyridine ketone hydrazone dithiocarbamte may influence respective function in proliferation and metastasis-related gene expressions in HepG2 cell.
- Role of Biomarkers in the Diagnosis and Prognosis of Acute Kidney Injury in Patients With Cardiorenal Syndromeon May 7, 2021 at 5:00 pm
Figure 2 illustrates the delay in rise of serum creatinine compared with biomarkers such as B-type natriuretic peptide (BNP) and neutrophil gelatinase-associated lipocalin (NGAL), which rise ...
- Global Renal Biomarker Market is estimated to be US$ 2230.2 million by 2030 with a CAGR of 7.50% during the forecast period - by PMIon May 4, 2021 at 8:07 am
Covina, CA, May 04, 2021 (GLOBE NEWSWIRE) -- The Global Renal Biomarker Market accounted for US$ 1084.5 million in 2020 and is estimated to be US$ 2230.2 million by 2030 and is anticipated to ...
- Global Renal Biomarker Market is estimated to be US$ 2230.2 million by 2030 with a CAGR of 7.50% during the forecast period - by PMIon May 4, 2021 at 7:07 am
The Global Renal Biomarker Market accounted for US$ 1084.5 million in 2020 and is estimated to be US$ 2230.2 million by 2030 ... gelatinase-associated lipocalin (NGAL), kidney injury molecule ...